|
| | Galeterone Basic information |
| Product Name: | Galeterone | | Synonyms: | (3β)-17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3-ol;(3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol;CS-232;VN/124-1; GALETERONE;TOK001;TOK 001;TOK-001;Galaterone;NX41765;(3S,8R,9S,10R,13S,14S)-17-(1H-Benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol;(3beta)-17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3-ol | | CAS: | 851983-85-2 | | MF: | C26H32N2O | | MW: | 388.55 | | EINECS: | 806-537-4 | | Product Categories: | Inhibitors;API | | Mol File: | 851983-85-2.mol |  |
| | Galeterone Chemical Properties |
| Melting point | 189-190℃ | | Boiling point | 564.5±60.0 °C(Predicted) | | density | 1.28 | | storage temp. | -20°C Freezer | | solubility | Chloroform (Slightly), Ethyl Aceatae (Slightly, Heated) | | pka | 14.71±0.70(Predicted) | | form | Solid | | color | White to Off-White |
| | Galeterone Usage And Synthesis |
| Description | Galeterone (TOK-001) is a small molecule oral drug that disrupts AR signaling by a novel triple mechanism: it potently and selectively inhibits CYP17 lyase, potently antagonizes AR and decreases AR protein levels (wild-type and mutant), leading to antitumor activity. Galeterone has shown significant anti-tumour activity with a well-tolerated safety profile in patients with CRPC in phase I and II clinical studies. | | Uses | Galeterone is an androgen receptor antagonist and CYP17A1 enzyme inhibitor. It has been used in trials studying the treatment of Prostate Cancer. | | Definition | ChEBI: Galeterone is a 3-hydroxy steroid. It has a role as an androgen. | | Biological Activity | The cytochrome P450 (CYP) isoform CYP17 is also known as steroid 17α-hydroxylase/17,20 lyase because it catalyzes both 17α-hydroxylase and 17,20 lyase reactions in the synthesis of steroids, including androgens, estrogens, glucocorticoids, and mineralocorticoids. Galeterone is a CYP17 inhibitor (IC50 = 300 nM) that has been shown to competitively block synthetic androgen binding (EC50 = 845 nM) and to antagonize the androgen receptor in transcriptional activation assays. Galeterone can inhibit the growth of castration-resistant prostate cancer cells with an IC50 value of 2.9 μM and demonstrates synergy with everolimus or gefitinib for growth inhibition. | | target | CYP17 | | storage | Store at -20°C | | Mode of action | Galeterone is an orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits three distinct mechanisms of action: 1) as an androgen receptor antagonist, 2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors, all of which may result in a decrease in androgen-dependent growth signaling. Localized to the endoplasmic reticulum (ER), the cytochrome P450 enzyme CYP17 (P450C17 or CYP17A1) exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces progestins, mineralocorticoids, glucocorticoids, androgens, and estrogens. | | references | [1]. devore n m, & scott e e. structures of cytochrome p450 17a1 with prostate cancer drugs abiraterone and tok-001. nature, 2012, 482: 116-119.
[2]. mallik i, davila m, tapia t, et al. androgen regulates cdc6 transcription through interactions between androgen receptor and e2f transcription factor in prostate cancer cells. biochimica et biophysica acta (bba) - molecular cell research, 2008,1783:1737-1744.
[3]. bruno r d, vasaitis t s, gediya l. k, et al. synthesis and biological evaluations of putative metabolically stable analogs of vn/124-1 (tok-001): head to head anti-tumor efficacy evaluation of vn/124-1 (tok-001) and abiraterone in lapc-4 human prostate cancer xenograft model. steroids, 2011,76: 1268-1279. |
| | Galeterone Preparation Products And Raw materials |
|
